key: cord-0991745-m88vln41
authors: Stauning, Marius Ahm; Altintas, Izzet; Kallemose, Thomas; Eugen-Olsen, Jesper; Lindstrøm, Mette Bendtz; Rasmussen, Line Jee Hartmann; Gamst-Jensen, Hejdi; Nehlin, Jan O; Andersen, Ove; Tingleff, Jens
title: Soluble urokinase plasminogen activator receptor as a decision marker for early discharge of patients with COVID-19 symptoms in the emergency department
date: 2021-03-26
journal: J Emerg Med
DOI: 10.1016/j.jemermed.2021.03.012
sha: d387e83be0f559a2d7af0ba963b493eced2e3096
doc_id: 991745
cord_uid: m88vln41

BACKGROUND: SARS-CoV-2 strains healthcare capacity. Better risk stratification, with discharge of patients with a predicted mild disease trajectory can ease this burden. Elevated blood soluble urokinase plasminogen activator receptor (suPAR) has previously been shown associated with risk of intubation in confirmed COVID-19 patients. OBJECTIVE: To evaluate if point-of-care measures of suPAR in patients presenting at the emergency department (ED) with symptoms of COVID-19 can identify patients that can be safely discharged. METHODS: Observational cohort study including all patients in the ED with symptoms of COVID-19 from March 19(th) to April 3(rd), 2020. Soluble urokinase plasminogen activator receptor was measured at first presentation. Review of electronic patient records 14 days after admission were used to assess disease trajectory. Primary endpoints were mild, moderate, severe, or very severe trajectory. The predictive value of suPAR, National early warning score (NEWS), C-reactive protein (CRP), and duration of symptoms (DOS) was calculated using receiver operating characteristics (ROC). RESULTS: Of 386 patients, 171 (44%) patients had a mild disease trajectory, 79 (20%) a moderate, 63 (16%) a severe, and 73 (19%) a very severe disease trajectory. Low suPAR was a strong marker of mild disease trajectory. Results suggest a cut-off for discharge for suPAR<2.0 ng/ml if suPAR is used as a single parameter, and 3.0 ng/ml when combined with NEWS=<4 and CRP<10 mg/l- CONCLUSION: suPAR is a potential biomarker for triage and safe early discharge of patients with COVID-19 symptoms in the ED. suPAR can be used even before SARS-CoV-2 status is known.

The SARS-CoV-2 pandemic places extraordinary pressure on the health care system and especially hospital bed capacity. [1, 2] For optimal utilization of hospital resources, biomarkers of disease severity are urgently needed to ensure safe and quick discharge of patients who will not develop severe disease. Several routine biomarkers are associated with severe illness and mortality in patients with confirmed COVID-19. These include white blood cell count, alanine aminotransferase (ALAT), lactate dehydrogenase (LDH), and C-reactive protein (CRP). [3] [4] [5] However, examination of these biomarkers has focused solely on patients with confirmed SARS-CoV-2. Furthermore, these biomarkers are not always predictable, as they only become abnormal after a COVID-19 infection turn into a severe trajectory. Testing for SARS-CoV-2 has long latency, and many hospitals have struggled with limited supplies of test kits. With a large patient intake, physicians are often forced to decide whether a patient should be admitted or discharged before SARS-CoV-2 status is known.

In combination with this, COVID-19 symptoms are broad and nonspecific, and safe discharge can therefore not be based on the SARS-CoV-2 status alone. In studies conducted before the SARS-CoV-2 pandemic, soluble urokinase plasminogen activator receptor (suPAR) has been shown to be a strong marker of readmission and mortality in all comers in the ED. [6, 7] suPAR is the soluble form of the membrane bound urokinase-type plasminogen activator receptor (uPAR). [8] The precise physiological role of suPAR is not yet fully understood, but it is considered to reflect the level of chronic inflammation and immune activation. [9] . Elevated suPAR is found in a wide range of diseases both, acute, chronic, non-communicable, and infectious. [9, 10] Soluble urokinase plasminogen activator receptor has been investigated in several viral infections, including Human Immunodeficiency Virus (HIV) , hepatitis B and C, Crimean-Congo hemorrhagic fever, and hantavirus. In all cases, elevated suPAR associates with clinical severity and mortality. [11] [12] [13] [14] [15] [16] Elevated suPAR has also been shown to be associated with increased severity in patients with respiratory diseases, such as pneumonia, chronic obstructive pulmonary disease, and sepsisrelated respiratory distress. [17] [18] [19] In the general population elevated suPAR is associated with the pace of biological aging, and cognitive decline.

[20] Thus, suPAR seems to reflect the individuals health status and capacity to fight disease. The higher the suPAR concentration -the worse the prognosis. suPAR is therefore a potential biomarker to aid decision making for safe and early discharge of patients with COVID-19 symptoms in the ED. However, as SARS-CoV-2 is a novel virus only a few studies have been conducted on suPAR in COVID-19 patients. Elevated baseline suPAR levels have been shown associated with risk of intubation and mechanical ventilation, as well as risk of acute kidney failure in confirmed COVID-19 patients. [21, 22] We aimed to evaluate if suPAR can stratify patients presenting with symptoms of COVID-19 according to their risk of developing a mild, moderate, severe, or very severe disease trajectory, regardless of SARS-CoV-2 status. Furthermore, we tested the addition of suPAR to National early warning score (NEWS) and CRP.

NEWS is widely used in European hospitals to identify patients at risk of deterioration. It consists of a simple algorithm based on heart rate, systolic blood pressure, respiratory rate, oxygen saturation, oxygen supplement, temperature, and level of consciousness. Maximum aggregated score is 20, and an aggregated score of 0-4 is considered a low clinical risk.

[23] CRP is a widely recognized marker of inflammation, with commercial available POC test.

[24] Both NEWS and CRP can thus be obtained without a central lab and could therefore be used in combination with POC suPAR at a very early stage.

A single center observational cohort study at the ED at (institution blinded) in the period from March 19th until April 3rd, and with follow-up until April 17th, 2020. We included all patients (24/7) who were admitted to the ED with suspicion of COVID-19 during the study period. Patients had suPAR measured at admission, but test results were not available to the attending ED doctor.

Hereafter, all patients followed routine patient courses through the ED and other hospital departments, regardless of suPAR values. Only patients >18 years of age are referred to the ED.

Patients were referred to the ED for hospital examination and observation after phone consultation with their general practitioner, the Medical Helpline 1813, or after examination by doctors in outpatient COVID-19 clinics handling patients with mild symptoms. The included patients were thus patients suspected of COVID-19, who could not be treated in the primary sector due to more severe symptoms and/or their general health status. Examination and treatment in the ED, as well as in the primary sector, are all covered by the universal public healthcare, without direct patient payment.

Clinical data at admission and patient trajectories were recorded after 14 days through the review of electronic health records (EHRs) by three ED doctors associated this study (names blinded).

Data were entered into a Research Electronic Data Capture program (REDCap). A manual with definitions was developed a priori to ensure uniform data entry. Discrepancies were discussed and resolved by consensus between the three reviewers. The EHR covers medical records from all EDs in the Capital Region of (country blinded) and the Region of (blinded), as well as information on drug prescriptions, and deaths in any part of (Blinded-the entire country).

From the EHR we recorded the following data at admission: systolic and diastolic blood pressure, pulse, respiratory rate, oxygen saturation, body temperature, NEWS, results of routine blood tests, result of chest x-ray, smoking habits, length of COVID-19 symptoms before contact to the ED, and whether patients lived in nursing homes or received home assistance. In addition, we registered whether patients were diagnosed with infections including COVID-19 prior to admission. Further, we registered relevant comorbidities including heart and lung disease, previous strokes, and inflammatory diseases (supplemental table 1).

The following blood tests were routinely analyzed at admission at the Department of Clinical Biochemistry: white blood cell counts, hemoglobin, creatinine, CRP, ALAT, LDH, and bilirubin.

White blood cell counts were analyzed using Sysmex-XN-9000 (Sysmex Corporation, Kobe, Japan).

The remaining blood tests were analyzed using COBAS-8000 (Roche Diagnostics, Mannheim, Germany).

suPAR was measured on-site using suPARnostic Quick Triage point-of-care (POC) test (ViroGates, Birkerød, Denmark), according to the manufactures instructions. [25] Blood (EDTA, 4 ml) was drawn on arrival and centrifuged for 3 minutes. 10 μl of plasma was mixed with 100 ul of the kit's accompanying dilution buffer and 60 μl of the mix applied to the POC test. Results were quantified using an aLF reader (QIAGEN, Hilden, Germany) after 20 minutes incubation. If results showed suPAR levels above the highest detection level (15 ng/ml), the plasma sample was further diluted, until results were <15 ng/ml, after which results were multiplied according to the dilution factor.

The lab technician performing the POC test was blinded regarding the clinical status of the patients. According to the manufacturer, the suPAR concentration measured with POC test is within maximum +/-10% deviation from suPAR measured with ELISA. The CV% of POC suPAR test is 10-29% with the highest variation at low suPAR concentration. [25] Patient trajectory 

SARS-CoV-2 testing was performed on all patients, as part of routine diagnostics, and analyzed at the Department of Clinical Microbiology using a RealStar® SARS-CoV-2 RT-PCR Kit RUO (Altona Diagnostics, Hamburg, Germany) adapted to a Roche flow system. The lower limit of detection was reported to be 50 copies of RNA.

Primary endpoints were defined as mild, moderate, severe, and very severe disease trajectory.

Very severe disease trajectory was defined as: One or more of; acute organ failure, admission to ICU, palliative care, or death.

Severe disease trajectory was defined as: No indication of very severe disease trajectory and one or more of; hospitalization more than 5 days, ongoing hospitalization at end of follow-up, CPAP, NIV, or high flow oxygen.

Moderate disease trajectory was defined as: No indication of very severe or severe disease trajectory and hospitalization for more than 24 hours or readmission.

Mild disease trajectory was defined as: No indication of very severe, severe, or moderate disease trajectory, i.e., hospitalization less than 24 hours, without readmission, high flow oxygen, CPAP, NIV, acute organ failure, admission to ICU, palliative care, or death.

Continuous variables are presented as median and interquartile range (IQR). Categorical variables are presented as number (n) and percentages (%). Variables were stratified according to primary endpoints and suPAR levels, and differences assessed by the Kruskal-Wallis or chi-square test.

The ability of suPAR to predict disease trajectory was evaluated by receiver operating characteristics (ROC), with a mild as well as a mild or moderate disease trajectory compared to all other as outcomes. To ensure safe discharge optimal cut-off values was based on optimizing the certainty of a "mild trajectory", as well as the certainty of a "mild or moderate trajectory". We therefore prioritized maximum specificity when calculating cut-offs. In other words, we calculated the probability of having a suPAR value below the cut-off if the patients had a "mild trajectory" as well as the probability of having a suPAR value below the cut off if the patients had a "mild or moderate trajectory". To evaluate changes in optimal cut-off at high specificity, we calculated cutoffs for specificity in increments of 0.01 in the range of 0.90 to 0.99.

To evaluate the effect of suPAR in combinations with parameters routinely used in patient allocation, a logistic regression model was fitted for a mild disease trajectory and for a mild or moderate disease trajectory compared to all other, with log2 suPAR, CRP (≤10/>10), NEWS (≤4/>4), and symptoms duration (≤5/>5 days) as independent variables. The linear predictor from this model was used in a ROC analysis calculating cut-offs at specificity 0.90 to 0.99. suPAR values equivalent to the linear predictor cut-off values were calculated for all combinations of independent variables. R 3.60 (R Foundation for Statistical Computing, Vienna, Austria) was used for statistical analysis and to create the figures. A P-value <0.05 was considered statistically significant.

The database and collection of clinical data were approved by the (country blinded) Data Protection Agency (record no. P-2020-513) and by the (country blinded) Patient Safety Authority (record no. 31-1521-319). No changes to routine clinical practice or treatment were applied. The study did not cause any delay in treatment or diagnostics.

We screened 415 patients and included 386. Reasons for exclusion were: No COVID-19 suspicion (n=19), no suPAR test in the ED (n=9), and technical reasons (n=1). We had no loss to follow-up.

Mean age was 64 years (IQR 46 -77) and 165 patients (43%) were male (table 1) . When baseline characteristics were stratified according to primary endpoints, significant differences were seen for suPAR, sex, age, white blood cell count, CRP, ALAT, creatinine, NEWS, no. of comorbidities, home assistance, nursing home, and new x-ray abnormalities (table 1) . 

Seven patients (4.1%) with mild disease trajectories received oxygen. All seven received non-high flow oxygen through a conventional face mask or nasal cannula (table 4) . Thirteen patients (7.6%) with a mild disease trajectory received antibiotics (table 4) . For patients with very severe disease trajectory, 71% received oxygen through a conventional mask or nasal cannula, 16% received mechanical ventilation, and 66% received antibiotics (table 4) . No patients with suPAR levels below 4.0 ng/ml (n=196) were transferred to ICU (table 3) .

suPAR as a single predictor of disease trajectory.

For patients with mild disease trajectory (n=36, 9%) ROC analysis showed that specificity for suPAR <2.0ng/ml was 93% and specificity for suPAR <3.0 ng/ml was 82% ( figure 1, table 5 ). For patients with either mild or moderate disease trajectory (n=120, 31%) specificity for suPAR <2.0 ng/ml was 96% and specificity for suPAR <3.0 was 88% (figure 2, table 5). Negative predictive value (NPV) for very severe disease trajectory was 100 % for suPAR <2 ng/ml and 94 % for suPAR <3 ng/ml (table   5) .

suPAR as a predictor of disease trajectory in combination with NEWS, CRP and duration of symptoms.

For patients with mild disease trajectory ROC analysis showed that specificity for the combination of suPAR <3 ng/ml CRP ≤10 and NEWS≤4 was 93 %. (figure 1, 

In summary, we found that suPAR levels were strongly associated with patient trajectories within 14 days, with low suPAR levels identifying patients with a mild disease trajectory.

Our results suggest that suPAR can aid physicians in the ED, in their decision of whether a patient presenting with COVID-19 symptoms should be admitted or discharged, without having the result of a SARS-CoV-2 test ready in hand. Based on our results, we can generate the following hypothesis: If suPAR is used as a single parameter, the results suggest that a suPAR level <2.0 ng/ml could be a possible cut-off for early discharge of patients with COVID-19 symptoms.

Specificity for suPAR <2 ng/ml was above 90% in both patients with mild disease trajectory and patients with either mild or moderate disease trajectories. ( figure 1 and 2 Our study included patients with COVID-19 symptoms regardless of SARS-CoV-2 test status, thus, disease trajectories cover both COVID-19 as well as non-COVID-19 complications in the patient group. Clinicians are therefore not forced to wait for SARS-CoV-2 testing to use the above stratifications and can also avoid admitting patients for observation waiting for progression or regression of symptoms. The severity of COVID-19 can increase dramatically during the first days after infection. A similar increase in the suPAR response is possible but has not yet been fully examined. To adjust for patients presenting early after infection, duration of symptoms was included in our analysis. But this addition did not change results compared to combinations only including suPAR, NEWS and CRP. It is likely that a wait-and-see approach will be suitable for patients with short duration of symptoms but with low suPAR, low NEWS, and low CRP. Patients could most likely be sent home for self-isolation and only be referred to hospital examination if symptoms progress. It should however be noticed that the combination of any three out of four of; suPAR<3 ng/ml, NEWS≤4, CRP<10 and duration of symptoms >5 days provides close to the same high specificity and NPV as a combination of all variables (figure 1 and 2, table 5).

As with all decisions to admit or discharge, the full clinical picture and health history of the patient should be considered. Our results are related to patients with COVID-19 symptoms; if the patients show symptoms or are diagnosed with other diseases, these should be considered and treated. It should also be noted that the aim of the study was to provide tools for a safe and early discharge before SARS-CoV-2 status is known. Discharged patients should self-isolate until results of SARS-CoV-2 testing is available and comply with local health-authorities' recommendations for further testing or isolation.

Our study is in agreement with studies conducted before the SARS-CoV-2 pandemic, where elevated suPAR was found to be a strong marker of disease severity, readmission, and mortality in patients admitted to the ED. [6, 7, 26] A recent position paper on suPAR in the ED suggests 4 ng/ml as a cut-off level for safe discharge. [27] However, this recommendation was based on a single study conducted before the SARS-CoV-2 pandemic, focusing primarily on mortality. [27] Our results suggest a lower cut-off value for safe discharge in patients with COVID-19 symptoms. Few studies have been conducted on suPAR in COVID-19 patients. Elevated suPAR levels have been shown associated with risk of intubation and mechanical ventilation, as well as risk of acute kidney failure in confirmed COVID-19 patients. [21, 22] A recent UK study found NEWS to be a good predictor of ICU admission and mortality in confirmed COVID-19 patients.

[28] This is an interesting result for in-hospital distribution of patients, however ICU and mortality are too narrow endpoints for ED discharge, and we have therefore also included readmissions, duration of hospitalization, and specific treatments in our analysis.

During a pandemic, testing is not always available, can have long latency, and may produce false negative results. Further, ED's are burdened by a large patient intake, creating ED overcrowding.

suPAR could enhance the clinical response and ensure a better distribution of resources, by identifying patients that can be early discharged without risk of complications. Our results are particularly relevant since suPAR was measured with a POC test which provided results in less than 30 min including time for collection and preparation of blood samples. The POC test could easily be implemented in the primary sector or temporary outpatient clinics and possibly aid in the decision on whom to refer for hospital examination. Further studies are needed to test the predictive value of suPAR in such settings. The role of suPAR has been investigated in many other viral diseases and has correlated well to disease severity. [11] [12] [13] [14] 

As a single-center study, we cover a relatively small (n=386) and homogeneous patient sample, primarily of Caucasian ethnicity. Further studies are needed to test suPAR's ability in larger and more diverse samples. The suggested cut-off values will thus require verification in prospective cohort studies or intervention studies. Our study has only included patients with COVID-19 symptoms referred to the ED, and we have therefore not been able to test hypotheses of suPAR's predictive value outside the ED setting. Further studies testing the value of suPAR in the primary sector will be of high relevance. In our study, we intended to examine suPAR's predictive ability at a very early stage, enabling physicians to apply the results regardless of SARS-CoV-2 test result.

We have therefore included patients with COVID-19 symptoms, rather than confirmed SARS-CoV-2. It is possible that the result would have been different if the study population were restricted to only including patients with confirmed SARS-CoV-2. Physicians had access to routine admission blood samples and chest x-ray when examining the patients. The isolated effect of suPAR can therefore not be examined in our study design. Our results suggest that suPAR in some patients possibly can replace broad admission blood samples and chest x-ray by identifying patients with a high chance of exhibiting a mild disease trajectory with the combination of a few simple parameters. Further studies are needed to test this hypothesis. An economic cost-benefit evaluation of suPAR in the ED is beyond the scope of this study. However, the cost of test equipment and sample preparation, should be viewed against the cost of admitting patients for observation. NEWS was updated in 2019 to NEWS-2.

[31] This update has not been incorporated at our hospital, but the only difference is a slight adjustment in pO 2 scale specific for patients with hypercapnic respiratory failure, while scoring of the remaining patients remain the same.

[31] It is highly unlikely that this adjustment would have resulted in different scores in the mild and moderate disease trajectory groups, and our result can therefore unproblematically be compared to studies using NEWS-2.

In conclusion, suPAR is a potential biomarker for triage of patients with COVID-19 symptoms in the ED. Our results suggest a cut-off value for discharge for suPAR at <2.0 ng/ml if suPAR is used as a single parameter, and 3.0 ng/ml if combined with NEWS <4, CRP <10 mg/l. Triage by suPAR can be used even before SARS-CoV-2 status is known.

SARS-CoV-2 places extraordinary stress on the health care system, and especially on hospital bed capacity. Better risk stratification, with early discharge of patients with a predicted mild disease trajectory could ease this burden.

First, to evaluate if point-of-care (POC) measures of blood level soluble urokinase plasminogen activator receptor (suPAR) in patients presenting at the emergency department, with symptoms of COVID-19, can identify patients that can be safely discharged.

Second, to estimate cut-off values of suPAR for safe discharge of patients with COVID-19 symptoms.

suPAR is a potential biomarker for safe, early discharge of patients with COVID 19 symptoms in the ED.

suPAR can be used even before SARS-CoV-2 status is known.

In the COVID-19 pandemic hospital resources must be used for the critically ill patients. Rapid POC measurement of suPAR can identify a group of patients with COVID-19 symptoms, who are at very low risk for severe disease trajectory. If this group is early discharged resources can be directed to those most in need. National Early Warning Score (NEWS) 2 | Standardising the assessment of acute-illness severity in the NHS. London: 2019. https://www.rcplondon.ac.uk/projects/outputs/national-early-warningscore-news-2 (accessed 9 Feb 2021). 0 (0%) 0 (0%) 0 (0%) 13 (17.8%) 13 (3.4%) Acute kidney failure, n (%) 0 (0%) 0 (0%) 0 (0%) 6 (8.2%) 6 (1.6%) Acute liver failure, n (%) 0 (0%) 0 (0%) 0 (0%) 4 (5.5%) 4 (1%) Acute lung failure, n (%) 0 (0%) 0 (0%) 0 (0%) 37 (50.7%) 37 (9.6%) Acute heart failure, n (%) 0 (0%) 0 (0%) 0 (0%) 6 (8.2%) 6 (1.6%) Received palliative care, n (%) 0 (0%) 0 (0%) 0 (0%) 28 (38.4%) 28 (7.3%) Died, n (%) 0 (0%) 0 (0%) 0 (0%) 35 (47.9%) 35 (9.1%) Died at home, n (%) 0 (0%) 0 (0%) 0 (0%) 8 (11%) 8 (2.1%) Died at hospital, n (%) 0 (0%) 0 (0%) 0 (0%) 27 (37%) 27 (7%)

Legend 

Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan

Locally Informed Simulation to Predict Hospital Capacity Needs During the COVID-19 Pandemic

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): A meta-analysis

Immunology of COVID-19: Current State of the Science

Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease

Combining national early warning score with soluble urokinase plasminogen activator receptor (SUPAR) improves risk prediction in acute medical patients: A registry-based cohort study

Soluble urokinase plaminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study

Cellular receptor for urokinase plasminogen activator

Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol

The intriguing role of soluble urokinase receptor in inflammatory diseases

Soluble urokinase plasminogen activator receptor (suPAR) as a prognostic marker of mortality in healthy, general and patient populations: Protocol for a systematic review and meta-analysis

Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: A cohort study

The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever

Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapy-mediated Viral Suppression | Clinical Infectious Diseases | Oxford Academic

Plasma Levels of Soluble Urokinase-Type Plasminogen Activator Receptor Associate with the Clinical Severity of Acute Puumala Hantavirus Infection

Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B

Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection

Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD

Levels of Soluble Urokinase Plasminogen Activator Receptor in Pediatric Lower Respiratory Tract Infections

Serum plasminogen activator urokinase receptor predicts elevated risk of acute respiratory distress syndrome in patients with sepsis and is positively associated with disease severity, inflammation and mortality

Association Between Elevated suPAR, a New Biomarker of Inflammation, and Accelerated Aging

Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia

Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI

A multicenter evaluation of a point of care CRP Test

Instructions for use, suPARnostic Quick Triage for aLF reader

Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy

Prognostic Role of Soluble Urokinase Plasminogen Activator Receptor at the Emergency Department: A Position Paper by the Hellenic Sepsis Study Group

Predicting intensive care unit admission and death for COVID-19 patients in the emergency department using early warning scores

Remdesivir for the Treatment of Covid-19 -Preliminary Report

The closer the specificity is to 1.0, the higher is the probability of values below cutoff in the given disease trajectory group. Very severe disease trajectory was defined as: One or more of; acute organ failure, admission to ICU, palliative care, or death. Severe 

Legend figure 1 : The closer the specificity is to 1.0 the higher is the probability of a mild disease trajectory. suPAR: Soluble urokinase plasminogen activator receptor (ng/ml). NEWS: National early warning score. CRP: C-reactive protein. The length of symptoms means duration from patients experienced first symptoms until first contact to the ED. Mild disease trajectory was defined as: Hospitalization less than 24 hours, without readmission, high flow oxygen, CPAP, NIV, acute organ failure, admission to intensive care treatment (ICU), palliative care, or death.Caption figure 2: Relationship between suPAR and specificity for a mild or moderate disease trajectory.

The closer the specificity is to 1.0 the higher is the probability of a mild or moderate disease trajectory. suPAR: Soluble urokinase plasminogen activator receptor (ng/ml). NEWS: National early warning score. CRP: C-reactive protein. The association between suPAR levels, other variables and specificity for a mild disease trajectory was calculated with logistic regression model and receiver operating characteristics (ROC). Mild disease trajectory was defined as: Hospitalization less than 24 hours, without readmission, high flow oxygen, CPAP, NIV, acute organ failure, admission to intensive care treatment (ICU), palliative care, or death. Moderate disease trajectory was defined as: Hospitalization less than 5 days, without high-flow oxygen, CPAP, NIV, acute organ failure, admission to ICU, palliative care, or death.